SLx-2101

DRUG3 trials

Sponsors

Response Pharmaceuticals, Retension Pharmaceuticals. Inc.

Conditions

HypertensionRaynaud's Disease

Phase 2

Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

CompletedNCT00528242

Response PharmaceuticalsRaynaud's Disease

Start: 2007-06-30End: 2008-03-31Updated: 2023-11-18

Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension

CompletedNCT00562549

Retension Pharmaceuticals. Inc.Hypertension

Start: 2007-07-01End: 2007-12-01Updated: 2026-04-30

Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension

CompletedNCT00562614

Retension Pharmaceuticals. Inc.Hypertension

Start: 2007-06-01End: 2007-12-01Updated: 2026-04-30